{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:49:51Z","timestamp":1790714991567,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Japanese Society of Chemotherapy"},{"name":"Japanese Society of Chemotherapy"},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sumitomo Dainippon Pharma Co. Ltd."},{"name":"Toyama Chemical Co. Ltd."},{"DOI":"10.13039\/100010793","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Becton"},{"name":"Dickinson and Company"},{"DOI":"10.13039\/501100005612","name":"Shionogi & Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"crossref"}]},{"name":"KYORIN Pharmaceutical Co., Ltd."},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taisho Toyama Pharmaceutical Co. Ltd."},{"name":"Japan Becton"},{"name":"Dickinson and Company"},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"bioM\u00e9rieux Japan Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jiac.2020.07.002","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T08:13:25Z","timestamp":1598602405000},"page":"1237-1243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia"],"prefix":"10.1016","volume":"26","author":[{"given":"Kenji","family":"Ota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihito","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2020.07.002_bib1","series-title":"Antibiotic resistance threats in the USA","first-page":"22","year":"2013"},{"key":"10.1016\/j.jiac.2020.07.002_bib2","series-title":"Antimicrobial resistance: global report on surveillance","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.jiac.2020.07.002_bib3","first-page":"376","article-title":"Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia","volume":"7","author":"Xu","year":"2015","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1469-0691.2012.03823.x","article-title":"Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria","volume":"18","author":"Akova","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2020.07.002_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1399-3062.2009.00374.x","article-title":"Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients","volume":"11","author":"Mathers","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"Van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jac\/dkn530","article-title":"Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa","volume":"63","author":"Aoki","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2020.07.002_bib9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/514732","article-title":"Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and acinetobacter baumannii","volume":"28","author":"Levin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","article-title":"Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?","volume":"17","author":"Daikos","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2020.07.002_bib12","first-page":"106","article-title":"In\u00a0vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae","volume":"3","author":"Le","year":"2011","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.jiac.2020.07.002_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jiac.2018.11.012","article-title":"Molecular and epidemiological analysis of IMP-1 metallo-\u03b2-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan","volume":"25","author":"Yamakawa","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2020.07.002_bib14","first-page":"1","article-title":"A\u00a0robust pneumonia model in immunocompetent rodents to evaluate antibacterial efficacy against S.\u00a0pneumoniae, H. influenzae, K. pneumoniae, P.\u00a0aeruginosa or A.\u00a0baumannii","author":"Hoover","year":"2017","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.jiac.2020.07.002_bib15","doi-asserted-by":"crossref","first-page":"O831","DOI":"10.1111\/1469-0691.12677","article-title":"In\u00a0vitro and in\u00a0vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae","volume":"20","author":"Harada","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2020.07.002_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: a critical review","volume":"19","author":"Andes","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2020.07.002_bib17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","article-title":"Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia","volume":"188","author":"Shindo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2020.07.002_bib18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1440-1843.2011.01983.x","article-title":"Clinical features of healthcare-associated pneumonia (HCAP) in a Japanese community hospital: comparisons among nursing home-acquired pneumonia (NHAP), HCAP other than NHAP, and community-acquired pneumonia","volume":"16","author":"Umeki","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.jiac.2020.07.002_bib19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/cid\/cit571","article-title":"A\u00a0new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy","volume":"57","author":"Maruyama","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib20","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2020.07.002_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/infdis\/jis766","article-title":"Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase\u2013producing K. pneumoniae","volume":"207","author":"Hirsch","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.002_bib22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.38028.520995.63","article-title":"\u03b2 lactam monotherapy versus \u03b2 lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials","volume":"328","author":"Paul","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2020.07.002_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","article-title":"Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary","volume":"11","author":"Chow","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2020.07.002_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jac\/19.4.487","article-title":"Efficacy of different dosing schedules of tobramycin for treating a murine klebsiella pneumoniae bronchopneumonia","volume":"19","author":"Pech\u00e8re","year":"1987","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2020.07.002_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1128\/AAC.01004-09","article-title":"Hydrolysis and inhibition profiles of \u03b2-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem","volume":"54","author":"Queenan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2020.07.002_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20302154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20302154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:00:26Z","timestamp":1761159626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X20302154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1341321X20302154"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2020.07.002","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2020.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}